Home > Pulmonology > ATS 2022 > Hydrocortisone does not help pre-term infants

Hydrocortisone does not help pre-term infants

Presented By
Prof. Namasivayam Ambalavanan, University of Alabama, AL, USA
Conference
ATS 2022
Hydrocortisone treatment in pre-term infants, starting on post-natal day 14 to 28, did not result in substantially higher survival without moderate or severe bronchopulmonary dysplasia (BPD) than placebo, according to the results of a randomised trial. Prof. Namasivayam Ambalavanan (University of Alabama, AL, USA) introduced the rationale for the study by stating that BPD is a prevalent complication after an extremely pre-term birth (<30 weeks gestation), which may partially be attributable to inflammation as a result of mechanical ventilation. It is unknown whether hydrocortisone treatment after the first post-natal week might be able to improve survival without BPD [1]. To that end, researchers determined the efficacy of hydrocortisone in facilitating extubation, thereby increasing survival without moderate or severe BPD, by initiating the Hydrocortisone and Extubation study (


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on